Atyr PHARMA FY2026 EPS Forecast Reduced by HC Wainwright

Atyr PHARMA INC (NASDAQ:ATYR) – Investment analysts at HC Wainwright reduced their FY2026 earnings estimates for Atyr PHARMA in a research report issued to clients and investors on Tuesday, April 29th. HC Wainwright analyst J. Pantginis now expects that the company will earn ($0.66) per share for the year, down from their prior estimate of ($0.53). HC Wainwright currently has a “Buy” rating and a $35.00 price objective on the stock. The consensus estimate for Atyr PHARMA’s current full-year earnings is ($0.91) per share. HC Wainwright also issued estimates for Atyr PHARMA’s FY2027 earnings at $0.39 EPS and FY2028 earnings at $0.50 EPS.

A number of other research analysts also recently commented on the company. Cantor Fitzgerald initiated coverage on Atyr PHARMA in a research note on Monday, January 6th. They set an “overweight” rating for the company. Leerink Partnrs raised shares of Atyr PHARMA to a “strong-buy” rating in a report on Tuesday, February 18th. Finally, Leerink Partners began coverage on shares of Atyr PHARMA in a report on Tuesday, February 18th. They issued an “outperform” rating and a $16.00 price objective on the stock. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $18.60.

Atyr PHARMA Stock Up 7.8 %

Shares of Atyr PHARMA stock opened at $3.60 on Friday. The stock has a market capitalization of $319.89 million, a price-to-earnings ratio of -3.83 and a beta of 0.95. Atyr PHARMA has a twelve month low of $1.42 and a twelve month high of $4.66. The company has a current ratio of 5.41, a quick ratio of 5.41 and a debt-to-equity ratio of 0.02. The business’s 50 day simple moving average is $3.29 and its 200-day simple moving average is $3.40.

Atyr PHARMA (NASDAQ:ATYR) last issued its earnings results on Thursday, March 13th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.05.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Group One Trading LLC acquired a new stake in Atyr PHARMA in the fourth quarter worth approximately $26,000. Alterna Wealth Management Inc. bought a new stake in shares of Atyr PHARMA in the 4th quarter worth $36,000. Victory Capital Management Inc. acquired a new stake in shares of Atyr PHARMA in the fourth quarter valued at $37,000. Raymond James Financial Inc. bought a new position in Atyr PHARMA during the fourth quarter valued at about $39,000. Finally, XTX Topco Ltd acquired a new position in Atyr PHARMA during the fourth quarter worth about $40,000. Institutional investors and hedge funds own 61.72% of the company’s stock.

About Atyr PHARMA

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.